Neurophet, an artificial intelligence (AI) company specializing in brain disease diagnosis and treatment, said Monday it will participate in the Alzheimer’s Association International Conference (AAIC) 2026, which will be held in London from July 12-15.
At the conference, the company will showcase Neurophet AQUA AD Plus, an integrated brain imaging analysis solution designed to support the prescription of Alzheimer’s disease therapies.
Neurophet AQUA AD Plus quantitatively analyzes MRI and PET scans to assist physicians throughout the treatment process, including evaluating patient eligibility before treatment, monitoring treatment-related side effects during therapy and assessing therapeutic outcomes after treatment.
The company will also exhibit Neurophet AQUA, its neurodegenerative brain imaging analysis software, and Neurophet SCALE PET, a quantitative PET image analysis platform.
Through its participation at AAIC 2026, Neurophet plans to pursue business development partnerships with global pharmaceutical and biotechnology companies as well as prospective customers for its imaging biomarker analysis services.
The company will also introduce its Imaging Core Lab (ICL) services, which analyze neuroimaging biomarkers widely used as key endpoints in clinical trials for Alzheimer’s and Parkinson’s disease therapies.
“Demand for Neurophet AQUA AD Plus is expanding among major domestic and international medical institutions in the field of imaging analysis for Alzheimer’s disease treatment,” said Bin Joon-gil, co-chief executive officer of Neurophet.
“We plan to accelerate strategic partnerships with global pharmaceutical companies and contract research organizations in the Imaging Core Lab business through our participation at AAIC 2026.”
Neurophet is a medical AI company developing AI-powered solutions for the diagnosis, analysis and treatment guidance of brain disorders.
The company was founded by co-CEOs Bin Joon-gil and Kim Dong-hyun, who developed a next-generation neuro-navigation system at the Gwangju Institute of Science and Technology (GIST), and now develops end-to-end solutions covering the full continuum of brain disease care, from diagnosis and treatment planning to therapeutic guidance.
